| Institution: | From the 3Department of Biology, Technion, Israel Institute of Technology, Haifa 32000, Israel;;4Rheumatology Unit, Bnai Zion Medical Center, Haifa 31048, Israel;;5Hospital Universitario Central de Asturias, 33011 Oviedo, Asturias, Spain;;6Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15,72076 Tuebingen, Germany;;**BioNTech AG, Holderlinstr. 8,55131 Mainz, Germany;;12Eberhard Karls Universität Tübingen, Department of Immunology, Auf der Morgenstelle 15,72076 Tubingen, Germany;;8Université de Genève, Rue Gabrielle Perret Gentil 4; 1211 Geneve 14, Switzerland;;9Heidelberg University Medical Center, Im Neuenheimer Feld 672, D-69120 Heidelberg, Germany;;10Leiden University Medical Center, Department of Medical Oncology, Albinusdreef 2, 2333 ZA Leiden, The Netherlands;;123Vall d''Hebron University Hospital, Institut Catala de la Salut, Pg. Vall d''Hebron 119-129, 08035 Barcelona, Spain;;84Cancer Sciences Division, Faculty of Medicine, University of Southampton, Southampton, UK;;95Association for Cancer Immunotherapy (CIMT), Langenbeckstr. 1,55131 Mainz, Germany;;106Region Hovedstaden (Center for Cancer Immune Therapy (CCIT), Herlev Hospital, Herlev Ringvej 75, DK-2730, Copenhagen, Denmark;;1212Rigshospitalet, Departments of Radiation Biology and Oncology, Rigshospitalet 9, Blegdamsvej, DK-2100, Copenhagen, Denmark;;88BCN Peptides, Pol. Ind. Els Vinyets-Els Fogars II. 08777 Sant Quinti de Mediona (Barcelona), Spain;;99University of California and the Parker Institute for Cancer Immunotherapy, San Francisco, CA 94131 |
